NO20004881L - Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor - Google Patents

Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor

Info

Publication number
NO20004881L
NO20004881L NO20004881A NO20004881A NO20004881L NO 20004881 L NO20004881 L NO 20004881L NO 20004881 A NO20004881 A NO 20004881A NO 20004881 A NO20004881 A NO 20004881A NO 20004881 L NO20004881 L NO 20004881L
Authority
NO
Norway
Prior art keywords
pyrrolo
pyrazine
atoms
similar
group
Prior art date
Application number
NO20004881A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004881D0 (no
Inventor
Mitsuaki Ohtani
Masahiro Fuji
Tetsuo Okada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20004881D0 publication Critical patent/NO20004881D0/no
Publication of NO20004881L publication Critical patent/NO20004881L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20004881A 1998-03-31 2000-09-28 Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor NO20004881L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP24473598 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (fr) 1998-03-31 1999-03-31 DERIVE DE PYRROLO[1,2-a]PYRAZINE INHIBANT sPLA¿2?

Publications (2)

Publication Number Publication Date
NO20004881D0 NO20004881D0 (no) 2000-09-28
NO20004881L true NO20004881L (no) 2000-11-28

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004881A NO20004881L (no) 1998-03-31 2000-09-28 Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor

Country Status (11)

Country Link
US (1) US6407104B1 (fr)
EP (1) EP1066290A1 (fr)
JP (1) JP4412521B2 (fr)
KR (1) KR20010042307A (fr)
CN (1) CN1303384A (fr)
AU (1) AU3054399A (fr)
BR (1) BR9909345A (fr)
CA (1) CA2326522A1 (fr)
HU (1) HUP0102981A3 (fr)
NO (1) NO20004881L (fr)
WO (1) WO1999051605A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329619T1 (de) 1998-10-14 2006-07-15 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
WO2001036420A1 (fr) * 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
WO2002012249A2 (fr) * 2000-08-04 2002-02-14 Eli Lilly And Company Nouveaux inhibiteurs du spla¿2?
TWI314457B (fr) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
CA2617532A1 (fr) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Derives d'imidazo [2,1-b] thiazole en tant que modulateurs de sirtuine
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2424521A4 (fr) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法
EP4378924A1 (fr) * 2021-09-17 2024-06-05 Mitsui Chemicals, Inc. Procédé de production d'un composé (méth)acrylamide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
CN1067054C (zh) 1994-04-01 2001-06-13 伊莱利利公司 1H-吲哚-3-乙醛酰胺sPLA2抑制剂
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
MX9700511A (es) 1994-07-21 1997-04-30 Lilly Co Eli Inhibidores de spla2 de indolizina.
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
BR9612347A (pt) 1995-12-13 1999-07-13 Lilly Co Eli Naftil acetamidas como inibidores de spla2
IL124871A (en) 1995-12-13 2002-04-21 Lilly Co Eli Naphthyl glyoxamides and medicinal preparations containing them, as inhibitors of sPLA2
TR199900956T2 (xx) 1996-10-30 1999-07-21 Eli Lilly And Company S�bstit�e edilmi� trisiklik bile�imler.
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Also Published As

Publication number Publication date
CN1303384A (zh) 2001-07-11
HUP0102981A3 (en) 2002-10-28
WO1999051605A1 (fr) 1999-10-14
JP4412521B2 (ja) 2010-02-10
HUP0102981A2 (hu) 2002-01-28
EP1066290A1 (fr) 2001-01-10
JP2002530268A (ja) 2002-09-17
KR20010042307A (ko) 2001-05-25
CA2326522A1 (fr) 1999-10-14
NO20004881D0 (no) 2000-09-28
AU3054399A (en) 1999-10-25
US6407104B1 (en) 2002-06-18
BR9909345A (pt) 2000-12-12

Similar Documents

Publication Publication Date Title
NO20004881L (no) Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor
BR9911048A (pt) Inibidor de spla2 de pirrolo[1,2-b]piridazina
NO20012570L (no) Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer
NZ507564A (en) 4-substituted carbazole or tetrahydrocarbazole derivatives
DK1106612T3 (da) Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
AU5702996A (en) Oxygen-containing heterocyclic compounds
IL156873A0 (en) Pharmaceutically active piperidine derivatives
EP0989129A4 (fr) Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
CO5011045A1 (es) Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos
DE69521500D1 (de) Phosphorsäurediester-derivate
DK0628550T3 (da) Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
TW352383B (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
TW200624541A (en) Flameproof rubber-reinforced styrenic resin composition
YU19099A (sh) Supstituisani tricikli
DK0746545T3 (da) Nipecotinsyrederivater som antithrombotiske forbindelser
NO934227L (no) Pyrrolderivater, fremgangsmåte for deres fremstilling og terapeutiske anvendelse
EP0133038A3 (fr) Dérivés d'acide octahydroindolizinepropionique comme inhibiteurs d'enzymes
AP2001002314A0 (en) Substituted benzolactam compounds.
BG102429A (en) Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means
AU4947996A (en) Arginine analogs acting as inhibitors of the NO synthase
ATE327982T1 (de) Benzylmorpholinderivate
ES543782A0 (es) Procedimiento de preparacion de un derivado 1,1-difenilpro- pan-1-ol